Activators of innate immunity may have the potential to combat a broad range of infectious agents. We report that treatment with bacterial flagellin prevented rotavirus (RV) infection in mice and cured chronically RV-infected mice. Protection was independent of adaptive immunity and interferon (IFN, type I and II) and required flagellin receptors Toll-like receptor 5 (TLR5) and NOD-like receptor C4 (NLRC4). Flagellin-induced activation of TLR5 on dendritic cells elicited production of the cytokine interleukin-22 (IL-22), which induced a protective gene expression program in intestinal epithelial cells. Flagellin also induced NLRC4-dependent production of IL-18 and immediate elimination of RV-infected cells. Administration of IL-22 and IL-18 to mice fully recapitulated the capacity of flagellin to prevent or eliminate RV infection and thus holds promise as a broad-spectrum antiviral agent.
R otavirus (RV) causes severe dehydrating diarrhea in young children and moderate intestinal distress in adults (1) . RV infection of adult mice serves as a well-defined model of intestinal viral infection in which infectivity can be monitored by measuring levels of viral antigen shed in feces (2) . RV predominantly infects and replicates in epithelial cells lining the small intestine (1) . Bacterial flagellin, the primary component of bacterial flagella, potently activates host defense gene expression in intestinal epithelial cells (IECs) (3) and is viewed as a dominant immune activator in the intestine (4) . Flagellin-induced gene expression confers both IECs and mice with resistance to a variety of challenges, including bacteria, chemicals, and radiation (5, 6) . Moreover, administration of flagellin reduced susceptibility of mice to a culture-adapted strain of RV (7) . Thus, we investigated the potential of flagellin to protect mice against highly contagious pathogenic mouse RV.
Oral inoculation of adult C57BL/6 mice with mouse RV (EC strain), using a dose 100,000 times that required to infect 50% of mice, resulted in uniform RV shedding that peaked 3 to 4 days after inoculation and resolved several days later, indicating viral clearance (2) . Administration of a single dose of flagellin via intraperitoneal injection shortly before infection temporarily prevented infection ( fig. S1A ). Repeated administration of flagellin further delayed (fig. S1B) or completely prevented infection (Fig. 1A ). In contrast, repeated administration of bacterial lipopolysaccharide (LPS) only transiently protected against RV infection ( fig. S2 ).
RV infection induces an adaptive immune response, which is normally required to clear infection (8) . However, we saw very little elevation in antibodies to RV in flagellin-treated mice ( fig.  S3 ), suggesting that flagellin's protection against RV was independent of adaptive immunity. Confirming this notion, the protective effect of flagellin was fully maintained in mice lacking recombination activating gene 1 (Rag1
), making them deficient in mature B and T lymphocytes and susceptible to chronic RV infection (Fig. 1B) (9) .
Analogous to young children, infection of neonatal mice with RV causes watery diarrhea (10). The incidence, duration, and active days of such RV-induced diarrhea and associated viral loads were reduced via flagellin treatment (Fig. 1, C and D). Flagellin treatment also diminished reovirus load after oral inoculation, suggesting broad antiviral activity ( fig. S4 ).
We next investigated whether flagellin could treat established chronic RV infection in immunecompromised mice. Although Rag1 −/− mice of all ages develop chronic RV infection, high viral loads are attained by infecting 3-week-old Rag1 −/− mice (9) . Flagellin treatment eliminated detectable RV shedding by 2 days after treatment. Moreover, 10 doses of flagellin treatment over a 20-day period abolished RV shedding for at least 150 days, whereas untreated mice shed virus over their lifetime (Fig. 1E) (12) . Flagellin can also be recognized intracellularly by the NOD-like receptor C4 (NLRC4) inflammasome, resulting in caspase 1-mediated production of the cytokines interleukin-1b (IL-1b) and IL-18 (13, 14) . We expected that only TLR5 would be required for flagellin protection against RV infection. However, loss of either pathway of flagellin recognition reduced, but did not completely eliminate, the capacity of flagellin to prevent RV infection (Fig. 2, A and B) . In contrast, absence of both TLR5 and NLRC4 or myeloid differentiation primary response gene 88 (MyD88), which is required for signaling by TLR5 and inflammasomeassociated cytokines, eliminated flagellin's protection against RV infection (Fig. 2, C and D) .
Next, we generated bone marrow chimeric mice using wild-type (WT) and Tlr5/Nlrc4 Nor were natural killer (NK) cells or intestinal macrophages required (figs. S10 and S11). Dendritic cells (DCs) mediate intestinal production of antibacterial peptides in response to flagellin (17) . To investigate whether these cells play a role in flagellin's antiviral effect, we generated chimeric mice in which bone marrow-derived cells were engineered to express the diphtheria toxin receptor (DTR) under control of the CD11c promoter so that CD11c-expressing cells, primarily DCs, could be depleted by the administration of diphtheria toxin (DT) (18) . Both DT-treated WT mice and untreated chimeric mice were protected against RV infection by flagellin treatment (Fig.  2E and fig. S12 ). However, flagellin was unable to protect DT-treated chimeric mice against RV infection (Fig. 2E) Mice were treated with PBS or flagellin (10 mg) every day from 0 to 9 days after inoculation and monitored for incidence of diarrhea daily (c 2 test, n = 11 mice, *P < 0.01). Flagellin-treated mice exhibited significantly reduced duration of diarrhea and days of active diarrhea (Student's t test, n = 11 mice, *P < 0.01). (D) Seven-day-old mice, treated as in (C), were euthanized 3 days after inoculation. Total RNA of small intestines from those mice were prepared and analyzed for RV NSP3 RNA level (Student's t test, n = 6 mice, *P < 0.05). (E) Three-week-old Rag1 −/− mice were inoculated with mouse RV. Three weeks after inoculation, at which point a chronic infection had been established, mice were treated with PBS T flagellin (20 mg) every 2nd day from 22 to 40 days after inoculation as indicated with red arrows. Feces were collected at indicated days and assayed for RV antigens by means of ELISA. Asterisk indicates that the difference between mice given PBS and flagellin was statistically significant. Results are shown as mean T SEM (two-way ANOVA, n = 5 mice, P < 0.0001). mice. Twelve hours later, the mice were studied as in (A) to (D). The difference between the PBS and flagellin groups was statistically significant in (G) (Student's t test on days 2 to 4, n = 4 mice, P < 0.05) but not (F) (Student's t test, n = 4 mice, P > 0.05 on all days). (H) Tlr5/Nlrc4 −/− mice were adoptively transferred with 20 million magnetic beadsorted DCs (purity > 95.0%) from WT C57BL/6 mice, and 12 hours later, the mice were studied as in (A) to (D) (Student's t test on days 2 to 5, n = 4 mice, P < 0.05). to (H) are shown as mean T SEM (n = 4 to 6 mice). The difference between mice given PBS and flagellin was statistically significant for (C) and (F) (two-way ANOVA, P < 0.0001) and significant at individual days of (A), (B), (D), (E), (G), and (H) [Student's t test, P < 0.05 on day 3 in (A), days 7 and 9 of (B), day 5 of (D), day 2 of (E), days 3 and 4 in (G), and days 3 and 4 in (H)].
Interferons (IFNs) play a central role in antiviral immunity. However, flagellin's antiviral effect was fully maintained in mice lacking type I and/or II IFN receptors or in mice lacking signal transducer and activator of transcription 1 (STAT1), which mediates IFN signaling ( fig. S13, A to D) . Nor did flagellin induce expression of type III IFN ( fig. S13E ), which is induced by RV (19) , or IFNassociated gene expression (20) . Thus, flagellin prevents and clears RV infection by a previously unrecognized antiviral pathway.
DC TLR5 activates the IL-12/IL-23 axis, resulting in innate lymphoid cells' (ILCs) production of IL-17 and IL-22 (17, 21) . Hence, we investigated whether ILC and this axis was involved in flagellin's antiviral action. Mice deficient in p40, which is a component of both IL-12 and IL-23, and Rag2/Il2rg −/− mice, which lack ILCs (and mature B and T lymphocytes), were not effectively protected by flagellin treatment (Fig. 3, A and B). Flagellin protection against RV infection was not affected by neutralization of IL-17 ( Fig.   3C ) but was almost completely abolished by genetic or antibody-mediated blockade of IL-22 ( Fig. 3, D and E) . These results suggest a central role for ILC-mediated IL-22 production in mediating flagellin's antiviral action. Accordingly, LPS does not elicit robust IL-22 production (21). Conversely, the requirement of NLRC4 suggested possible roles for inflammasome cytokines IL-1b and IL-18. Ablation of IL-1 receptor signaling modestly impaired flagellin's protection against RV infection, whereas two different means of IL-18 ablation markedly reduced flagellin's antiviral effect (Fig. 3, F to H ). In contrast to flagellin-induced IL-22 production, which requires ILCs, and DC expression of TLR5 ( fig.  S7 ) (22), flagellin-induced IL-18 production was unimpaired in Rag2/Il2rg −/− or DC-ablated mice ( fig. S7 ), indicating that distinct signaling events drive IL-22 and IL-18 production in distinct cell types. We next investigated the extent to which recombinant IL-22 and IL-18 recapitulate flagellin's antiviral action. When administered prophylactically, IL-18 or IL-22 had only partial protective efficacy, but together conferred complete protection against a broad range of RV inoculation (Fig. 4A and fig. S14 ). Moreover, co-administration of IL-18 and IL-22 eliminated viral shedding in chronically RV-infected Rag1 −/− mice (Fig. 4B) .
These results did not reflect a strong dependence on one of these cytokines for driving the expression of the other in that flagellin-induced IL-18 expression is independent of TLR5 (14), whereas flagellin-induced IL-22 is largely independent of NLRC4 ( fig. S15) after inoculation (indicated with red arrows). Difference between PBS and IL-22/IL-18 groups was statistically significant (two-way ANOVA, n = 4 mice, P < 0.0001). (C) Seven-day-old C57BL/6 mice were orally inoculated with RV. Mice were administered 50 ml PBS (vehicle) or 1 mg IL-22 plus 0.2 mg IL-18 immediately before inoculation, and 1 to 9 days after inoculation, and monitored for incidence of diarrhea daily (c 2 test, n = 5 to 6 mice, *P < 0.05), duration and active days of diarrhea (Student's t test, n = 5 to 6 mice, *P < 0. contrast to flagellin, was effective in mice lacking ILCs ( fig. S16 ). Like flagellin, prophylactic IL-22/IL-18 administration also afforded protection against the severe diarrhea seen in neonates (Fig. 4C) fig. S18) . Hence, to investigate mechanisms by which IL-22 and IL-18 treatment cleared RV infection, we examined signaling events in gut epithelial cells isolated from chronically RV-infected mice treated with IL-22, IL-18, or both cytokines. RNA sequencing revealed that IL-22 treatment induced rapid reprogramming of epithelial cell gene expression, implicating genes involved in a broad array of cellular processes (Fig. 4D and figs. S19 and S20) . A more modest effect was observed in response to IL-18, whereas the combination of IL-22 and IL-18 induced a number of changes in gene expression not seen with either cytokine alone. In contrast, administration of IL-18 but not IL-22 to RV-infected mice resulted in rapid activation of caspase 3, suggesting involvement of apoptosis ( fig. S21) . Thus, IL-22 and IL-18 induced changes in gene expression and caspase 3 activation that correlated with rapid blockade of RV replication and elimination of RV genomes within 24 hours of cytokine treatment (Fig. 4, E and  F) . Together, these data suggest that IL-18 induces signaling events that lead to rapid reduction in RV levels, whereas IL-22 reprograms epithelial cell gene expression, resulting in resistance to RV infection.
We demonstrate that innate immunity can be harnessed to prevent and treat viral infection. Given the health burden caused by RV, including 600,000 annual deaths in children (23) and chronic infections in immune-compromised hosts, this strategy presents a therapeutic opportunity, differences between human and mouse RV strains (24) notwithstanding. Moreover, the complex antiviral action of flagellin was fully recapitulated by IL-22 and IL-18, whose use could circumvent differences in NLRC4 function between mice and humans (25) . The action of these cytokines would likely be synergistic with therapies that directly target viruses and/or those that promote adaptive immunity. Thus, we propose activation of innate immunity with flagellin, or IL-22 and IL-18, as a potential strategy to combat emerging and recalcitrant viral pathogens.
